Vor Biopharma Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VOR Nasdaq 2836 www.vorbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vor Biopharma Inc.

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR) - Oct 4th, 2026 10:05 am
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis - Sep 29th, 2026 6:05 am
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight - Sep 16th, 2026 8:31 am
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - Sep 8th, 2026 5:00 am
Vor Bio To Participate in Upcoming September Conferences - Sep 1st, 2026 6:00 am
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 11th, 2026 7:30 am
Vor Bio Appoints David Zaccardelli to Board of Directors - Jul 7th, 2026 2:01 pm
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 2nd, 2026 3:30 pm
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next - Jun 30th, 2026 9:08 am
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China - Jun 8th, 2026 6:31 am
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China - Jun 8th, 2026 6:30 am
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - May 30th, 2026 12:12 pm
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - May 30th, 2026 10:48 am
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:30 am
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely - May 15th, 2026 6:25 am
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine - May 14th, 2026 6:30 am
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 13th, 2026 6:30 am